Update shared on 11 Dec 2025
Analysts have maintained their price target for Rubicon Organics at 1.15 dollars, reflecting largely unchanged assumptions for growth, profitability, and valuation multiples in their updated models.
What's in the News
- Rubicon Organics appointed Glen Ibbott, former Aurora Cannabis CFO with over 25 years of life sciences and cannabis finance leadership, as its new Chief Financial Officer after serving six months in an interim capacity (Key Developments).
- The company’s new Cascadia facility in Hope, British Columbia received a Health Canada license to cultivate, process, and store cannabis, enabling operations at a 47,500 square foot indoor site equipped with advanced cultivation technologies (Key Developments).
- The Cascadia facility adds an expected 4,500kg of annual production capacity, bringing Rubicon’s total to approximately 15,500kg of premium cannabis, with first revenues anticipated in the first half of 2026 (Key Developments).
Valuation Changes
- Fair Value: Unchanged at CA$1.15 per share, indicating no revision to the base case valuation.
- Discount Rate: Edged down fractionally from 6.118 percent to 6.118 percent, effectively unchanged in practical terms.
- Revenue Growth: Maintained at approximately 15.22 percent annually, with only immaterial rounding refinements in the model.
- Net Profit Margin: Essentially flat at about 2.89 percent, reflecting only a negligible technical adjustment.
- Future P/E: Steady at roughly 4451.8x, signaling no change in the long term earnings multiple assumption.
Have other thoughts on Rubicon Organics?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeDisclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.